Clinical Trial

A Trial of SHR-1905 in Subjects With Severe Uncontrolled Asthma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a phase 2 study of SHR-1905 in subjects with severe uncontrolled asthma. The purpose of the study is to evaluate efficacy and safety of SHR-1905 in subjects with severe uncontrolled asthma.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-10-20; most recent amendment 2026-06-03.
Status change: Recruiting → Active, Not Recruiting 2025-01-22
Status change: Enrolling by Invitation → Recruiting 2024-06-19
Status change: Recruiting → Enrolling by Invitation 2023-02-01
Status change: Not Yet Recruiting → Recruiting 2022-11-10
Trial Details
NCT Number NCT05593250
Lead Sponsor Shanghai Hengrui Pharmaceutical Co., Ltd.
Conditions Asthma
Enrollment 260 participants
Start Date 2023-01-17
Primary Completion 2026-12-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-05